Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-3846

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-3846). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals.inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3846 3)

Label for Losartan Potassium 100 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The package contains 30 tablets. The label includes NDC 68071-3846-3, manufacturer information, and storage instructions to keep at controlled temperature 68-77°F. The label also states Rx Only and a warning to keep out of reach of children.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure diagram of Losartan Potassium showing its molecular components, including chlorinated pyrimidine, biphenyl, and tetrazole groups with a potassium ion.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with the primary endpoint over study months for Atenolol and Losartan Potassium. The graph shows a lower percentage for Losartan Potassium with an adjusted risk reduction of 13% and a p-value of 0.021, across a study period up to 66 months.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients experiencing fatal or non-fatal stroke over a study period of 66 months between Atenolol and Losartan Potassium. The graph shows risk reduction of 25% for Losartan Potassium with statistical significance (p=0.001). The x-axis represents study months, and the y-axis represents percentage of patients with stroke.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart titled 'Figure 3: Primary Endpoint Events within Demographic Subgroups' comparing event rates and hazard ratios between Losartan Potassium and Atenolol. The chart displays data for primary composite endpoints and stroke (fatal/non-fatal) across demographic subgroups including age, gender, race, ISH status, diabetes, and history of cardiovascular disease, with hazard ratios and confidence intervals indicating the relative outcomes between the two treatments.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing the percentage of patients with an event over 48 months between groups receiving Losartan Potassium and placebo. The y-axis shows % patients with event, and the x-axis shows time in months. The graph indicates a risk reduction of 16.1% with a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.